Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

Background The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0 mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in subjects with type 2 diabetes (T2D) and high CV risk. The effects of gender, age and baseline CV risk on outcomes are importan...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Cardiovascular diabetology Ročník 18; číslo 1; s. 73 - 12
Hlavní autori:	Leiter, Lawrence A., Bain, Stephen C., Hramiak, Irene, Jódar, Esteban, Madsbad, Sten, Gondolf, Theis, Hansen, Thomas, Holst, Ingrid, Lingvay, Ildiko
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London BioMed Central 06.06.2019 Springer Nature B.V BMC
Predmet:	Age Age Factors Aged Angina pectoris Angiology Antidiabetics Baseline cardiovascular risk Blood pressure Body weight Cardiology Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - diagnosis Cardiovascular Diseases - mortality Cardiovascular Diseases - prevention & control Cardiovascular events Cerebral infarction Cholesterol Clinical medicine Clinical Trials, Phase III as Topic Coronary artery Coronary artery disease Demography Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - mortality Drug Administration Schedule Epidermal growth factor receptors Female Gender Gender differences Glucagon Glucagon-like peptide 1 Glucagon-Like Peptides - administration & dosage Glucagon-Like Peptides - adverse effects Health risk assessment Heart attacks Heart diseases Heart failure Heart surgery Hospitalization Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Incretins - administration & dosage Incretins - adverse effects Ischemia Kidney diseases Male Medicine Medicine & Public Health Middle Aged Myocardial infarction Original Investigation Patients Protective Factors Randomized Controlled Trials as Topic Risk Assessment Risk Factors Semaglutide Sex Factors Smoking Stenosis Stroke Systematic review Time Factors Treatment Outcome Type 2 diabetes Type 2 diabetes Cardiovascular events Semaglutide Baseline cardiovascular risk Gender Cardiovascular outcome trial Age SUSTAIN 6
ISSN:	1475-2840, 1475-2840
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!